Results 251 to 260 of about 285,968 (309)

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. [PDF]

open access: yesGynecol Oncol, 2015
Liao JB   +5 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Biomimetic Membrane Interface Technologies for Detection and Isolation of CTCs and EVs: Advances and Opportunities in Liquid Biopsy

open access: yesAdvanced Science, EarlyView.
Biomimetic membrane interface engineering constructs functionalized detection platforms by integrating natural cell membranes, synthetic lipids, or hybrid membranes. This strategy effectively reduces background interference and enables efficient target capture and analysis, showing broad applications in circulating tumor cell separation, extracellular ...
Duo Liu   +8 more
wiley   +1 more source

Nanozymes Integrated Biochips Toward Smart Detection System

open access: yesAdvanced Science, EarlyView.
This review systematically outlines the integration of nanozymes, biochips, and artificial intelligence (AI) for intelligent biosensing. It details how their convergence enhances signal amplification, enables portable detection, and improves data interpretation.
Dongyu Chen   +10 more
wiley   +1 more source

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu   +11 more
wiley   +1 more source

Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective. [PDF]

open access: yesBMC Res Notes, 2016
Hashmi AA   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy